The short version.

• Hospitals have permitted 100 per cent FDI on the automatic route since January 2000 — one of the oldest fully open sensitive sectors, no government approval needed.
• Actual inflow has stayed small: $8.89 billion cumulative into “Hospital & Diagnostic Centres” from April 2000 to June 2023, against roughly $21.6 billion for Drugs & Pharmaceuticals over a similar span, and a shrinking single-digit share of total FDI — 4.3% of all inflow in CY2023, down to 2.0% in H1 2025.
• Almost every large deal since 2023 is private equity or a sovereign fund buying an existing hospital chain — Temasek/Mubadala into Manipal, Blackstone into Care Hospitals and KIMS, Blackstone/TPG into Aster DM, KKR into Medicover’s Indian hospitals — not a new hospital being built.
• India has roughly 1.4–1.6 hospital beds per 1,000 people against a global average around 3.3 (not, as often claimed, a formal WHO minimum standard) and an OECD average near 4.7; government facilities alone run at just 0.79 per 1,000. Neither figure has moved because of this capital.
• Industry commentary is explicit that roll-ups beat greenfield builds on speed and cost even though new hospitals reportedly earn better margins — the opposite of what a capacity-shortage story would predict investors to do.

A sector that has been open longer than almost anything else

Hospitals and diagnostic centres have sat on India’s automatic FDI route — no government approval, no sectoral cap — since January 2000. That predates most of the liberalisation India is usually credited for. Two adjacent categories are frequently confused with it and carry different rules: greenfield pharmaceutical manufacturing is 100 per cent automatic but brownfield pharma (buying an existing plant) is capped at 74 per cent automatic beyond which government approval is required, and health insurance sits under the general insurance cap of 74 per cent automatic. Hospitals themselves have none of those caps. If foreign capital wanted to build or buy Indian hospital capacity at scale, the policy has not been the obstacle for a quarter of a century.

The money that actually showed up

Despite the open door, the sector stayed small relative to its own healthcare-manufacturing sibling, and its share of total FDI has been falling, not rising.

DPIIT Consolidated FDI sector-wise tables, calendar-year and cumulative-to-date figures as published in successive fact sheets (Table 3.3 Jan2000–Dec2022, Table 4 Jan2000–Jun2023, Table 4.3 CY2023, Table 8 H1 2024 and H1 2025). Blank cells are years the same table did not separately publish. DPIIT reports on a calendar-year basis; unrelated financial-year figures circulating in trade press (e.g. a widely cited “89% growth in FY2023-24”) cannot be reconciled against this table and are flagged here as a methodology mismatch, not a contradiction of it.

Who is actually writing the cheques

What inflow there is has concentrated hard into a specific kind of transaction: a private equity firm or sovereign wealth fund buying a controlling or large minority stake in an existing hospital chain, almost never a new hospital being built from the ground up.

Compiled from contemporaneous business-press and deal-advisory reporting (Business Standard, Bloomberg, Reuters/TradingView, DealStreetAsia, Trilegal, BioSpectrum India, Mubadala’s own release). Deal sizes for some transactions are reported as combined-platform figures rather than single-transaction prices and are noted as such; treat them as order-of-magnitude, not audited consideration. Industry-wide PE plus FDI into hospitals is estimated at roughly $8bn across 2022–2024 (PE about $5bn, FDI about $3.2bn per Bain’s 2024 healthcare private-equity report), against a healthcare and pharma M&A-and-PE total of $30bn-plus over the same window.

Every deal above is a change of ownership of beds that already existed. None of them, on the reporting available, is a foreign-financed hospital built where one was not standing before.

Why roll-ups, not new beds

Analyst and trade-press commentary on this wave of consolidation is unusually direct about the mechanism: buying an operating hospital delivers scale and cost synergies — shared supply chains, centralised procurement, a management layer spread across more beds — in months, where a greenfield hospital takes years to plan, build, staff and fill. That holds even though the same commentary reports greenfield hospitals earning better post-tax margins, around 10–12 per cent, than an acquired asset typically does once the purchase price is serviced. Nearly half of India’s leading hospital chains are now owned or controlled by global private equity. Industry projections do point to roughly 30,000 additional beds, about ₹35,000 crore of capex, over the next four to five years, concentrated in non-metro “emerging healthcare hubs” — but this is sector-wide domestic capex planning, not a specifically foreign-financed greenfield programme, and no foreign-branded new hospital entrant or hospital-focused REIT was found in the reporting used for this piece.

The shortage the deals do not touch

The commonly cited case for hospital investment is a straightforward capacity gap.

India, world and OECD bed-ratio figures independently checked against the World Bank’s own WHO-sourced series (indicator SH.MED.BEDS.ZS, api.worldbank.org, pulled 23 August 2026); the 0.79 government-only figure is a narrower trade-press citation (The South First) that the World Bank series does not separately break out. No single authoritative health-insurance-penetration percentage tied to a named primary source (IRDAI or otherwise) was found in the research for this piece; a reader who needs that figure for a decision should pull it directly from IRDAI’s own annual report rather than an unattributed industry citation.

None of the deals in the table above materially changes either bed-ratio figure, because none of them adds beds — they move ownership of beds that were already open. Whatever is closing India’s capacity gap, on the evidence gathered here, it is not the transactions that make the FDI headlines.

A sample of who runs what, and where

Ownership of Indian hospital capacity now sits across three groups: state-run teaching hospitals and AIIMS institutes, large private chains still largely under founder or promoter control, and private chains now majority- or significantly-owned by foreign private equity or sovereign funds. A sample by state:

Illustrative flagship institutions per state, not an exhaustive list of every hospital. Public entries are the best-known state or central teaching hospital in that state; private entries are the largest or best-known chains headquartered or operating at scale there. “Foreign PE / SWF stake” marks the specific chains named in the deal table above; a “No” means no such deal was found in this research, not a guarantee the group has zero foreign portfolio (FII) shareholding, which is a different and much smaller form of exposure than a private-equity control stake.

What to watch

• Whether the ~30,000-bed capex pipeline actually breaks ground on the timeline projected, and whether any of it is foreign-financed rather than domestic-chain capex.
• Whether hospital FDI's falling share of total inflow (4.3% to 2.0% across three periods) continues to fall once the current wave of large roll-up deals is digested.
• Pricing and affordability scrutiny of PE-owned hospital chains — already the subject of critical commentary and reportedly a parliamentary panel's questions — as roughly half the leading chains pass into PE hands.
• Whether the government publishes an updated, sourced bed-per-1,000 figure, since the 1.4 and 3.5 numbers currently driving the investment narrative are industry-repeated rather than freshly audited.

The honest summary

India opened hospitals to unrestricted foreign ownership in 2000 and has spent twenty-five years waiting for that door to be walked through at scale. It finally has been — but by buyers whose business model is acquiring cash-flowing hospitals and running them more efficiently, not underwriting the multi-year risk of building new ones. That is a rational, unremarkable thing for private equity to do. It is a different thing from what the sector's own bed-shortage numbers imply is needed, and nothing in the current wave of deals suggests the two will converge on their own.

Sources and caveats